Zobrazeno 1 - 10 of 259 pro vyhledávání: '"Jerold S. Harmatz"'
1
Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy
Autor: David J. Greenblatt, Christopher D. Bruno, Jerold S. Harmatz, Qingchen Zhang, Christina R. Chow
Publikováno v: Journal of clinical pharmacologyReferences. 62(11)
In 1979, the late Dr. Darrell R. Abernethy and colleagues began a series of clinical studies aimed at understanding the pertinent determinants of drug distribution, elimination, and clearance in obesity, and how those variables are interconnected. Th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa126759a7ac9dff257544cf005df451
https://pubmed.ncbi.nlm.nih.gov/35661375
Zobrazit plný text záznamu
3
Mechanism of dasabuvir inhibition of acetaminophen glucuronidation
Autor: Jerold S. Harmatz, Su Xiang Duan, Qingchen Zhang, David J. Greenblatt, Christopher A Singleton, Zixuan Wei
Publikováno v: The Journal of pharmacy and pharmacology. 74(1)
Objectives Acetaminophen (APAP) (paracetamol) is a widely used non-prescription drug for pain relief and antipyretic effects. The clearance of APAP is mainly through phase-2 biotransformation catalysed by UDP-glucuronosyl transferases (UGT). Dasabuvi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8214e1cffe8aab5f893bfe4f76dbf8a8
https://pubmed.ncbi.nlm.nih.gov/34718654
Zobrazit plný text záznamu
4
Effect of lipophilicity on drug distribution and elimination: Influence of obesity
Autor: Christina R. Chow, Qingchen Zhang, Jerold S. Harmatz, David J. Greenblatt, Su X. Duan, Christopher D. Bruno
Publikováno v: British journal of clinical pharmacologyREFERENCES. 87(8)
Aims For a given passively-distributed lipophilic drug, the extent of in vivo distribution (pharmacokinetic volume of distribution, Vd ) in obese individuals increases in relation to the degree of obesity. The present study had the objective of evalu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16300d8988b190184e4fd1b520297148
https://pubmed.ncbi.nlm.nih.gov/33450083
Zobrazit plný text záznamu
5
Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly
Autor: David J. Greenblatt, Yuxi Chen, Richard I. Shader, Qingchen Zhang, Jerold S. Harmatz
Publikováno v: Journal of clinical pharmacologyReferences. 61(2)
Age-related changes in disposition of diazepam and its principal active metabolite, desmethyldiazepam (DMDZ), during and after extended dosage with diazepam were studied in healthy volunteers. Eight elderly subjects (ages 61-78 years) and 7 young sub
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cb0f21e8e03049c914e36d6717c218d2
https://pubmed.ncbi.nlm.nih.gov/32856316
Zobrazit plný text záznamu
6
Resveratrol glucuronidation in vitro: potential implications of inhibition by probenecid
Autor: Bahar Matin, Ahmad A Sherbini, David J. Greenblatt, Jerold S. Harmatz, Novera Alam
Publikováno v: Journal of Pharmacy and Pharmacology. 71:371-378
Objectives Resveratrol is a naturally occurring antioxidant with therapeutic potential in prevention and treatment of neoplastic disease and other human disorders. However, net clearance of resveratrol in humans is very high, mainly due to glucuronid
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd209fc20fb38b425f22bdfe34a5143e
https://doi.org/10.1111/jphp.13037
Zobrazit plný text záznamu
7
Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole
Autor: David J. Greenblatt, Christina R. Chow, Jerold S. Harmatz, Michael J. Ryan
Publikováno v: Journal of Clinical Psychopharmacology. 38:289-295
Purpose/background The antipsychotic agent lurasidone (Latuda®) is metabolized by Cytochrome P450-3A (CYP3A) enzymes. Coadministration with strong CYP3A inhibitors (such as ketoconazole, posaconazole, and ritonavir) is contraindicated due to the ris
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5023d3ac8ac3f52ca4d923d0b6a31790
https://doi.org/10.1097/jcp.0000000000000892
Zobrazit plný text záznamu
9
Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection
Autor: Christopher M. Rubino, Christina R. Chow, Wayne T. Nicholson, David J. Greenblatt, Jerold S. Harmatz, Maulik Patel
Publikováno v: The Journal of Clinical Pharmacology. 58:533-540
Pharmacokinetics and antithrombotic effects of the Factor Xa inhibitor rivaroxaban were studied in subjects with mild renal insufficiency concurrently taking the P-glycoprotein and moderate CYP3A inhibitor verapamil, a drug commonly administered to p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f1f3558aa1f4ad2df3dd1bbf98d9eb
https://doi.org/10.1002/jcph.1040
Zobrazit plný text záznamu
10
Zolpidem and Gender: Are Women Really At Risk?
Autor: Thomas Roth, David J. Greenblatt, Jerold S. Harmatz
Publikováno v: Journal of clinical psychopharmacology. 39(3)
BACKGROUND In 2013 the Food and Drug Administration (FDA) claimed the existence of new data showing women to be at risk for excessive daytime sedation and impaired driving proficiency following bedtime doses of zolpidem. The putative explanation was
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d7aea9c94d0f447a000b2e6f23a6b5a
https://pubmed.ncbi.nlm.nih.gov/30939589
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje